Papers related to the phase 4 clinical trial for kidney dialysis delay of PureSphere's PureCarbon-derived oral adsorbent (Renamezine, prescription drug).

1. S.H. Kim, et al., New oral spherical carbon adsorbent effectively reduces serum indoxyl sulfate levels in moderate to advanced chronic kidney disease patients: a multicenter, prospective, open-label study, BMC Nephrology, 21 (2020) 317.

2. Y.K. Kee., et al., Comparison of different types of oral adsorbent therapy in patients with chronic kidney disease: A multicenter, randomized, phase IV clinical trial, Yonsei Medical Journal, 62(1) (2021) 41.

3. H.C. Park, et al., Effect of Renamezin upon attenuation of renal function decline in pre-dialysis chronic kidney disease patients: 24-week prospective observational cohort study, PLOS ONE, 16(6) (2021) e0252186.

4. R.H. Cha, et al., Effects of AST‐120 on muscle health and quality of life in chronic kidney, Journal of Cachexia, Sarcopenia and Muscle, 13 (2022) 397.

5. M.Y. Han, et al., Factors associated with gait speed: results from the RolE of AST120 (Renamezin) in sarCOpenia preVEntion in pRe-dialYsis chronic kidney disease patients (RECOVERY) study, Kidney Research and Clinical Practice, (2023) j.krcp.22.143.

PureCarbon	Renamezin (oral adsorbent)